Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Feb;37(2):478-487.
doi: 10.1038/s41375-022-01792-x. Epub 2022 Dec 16.

Asxl1 deletion disrupts MYC and RNA polymerase II function in granulocyte progenitors

Affiliations

Asxl1 deletion disrupts MYC and RNA polymerase II function in granulocyte progenitors

Theodore P Braun et al. Leukemia. 2023 Feb.

Abstract

Mutations in the gene Additional Sex-Combs Like 1 (ASXL1) are recurrent in myeloid malignancies as well as the pre-malignant condition clonal hematopoiesis, where they are universally associated with poor prognosis. However, the role of ASXL1 in myeloid lineage maturation is incompletely described. To define the role of ASXL1 in myelopoiesis, we employed single cell RNA sequencing and a murine model of hematopoietic-specific Asxl1 deletion. In granulocyte progenitors, Asxl1 deletion leads to hyperactivation of MYC and a quantitative decrease in neutrophil production. This loss of granulocyte production was not accompanied by significant changes in the landscape of covalent histone modifications. However, Asxl1 deletion results in a decrease in RNAPII promoter-proximal pausing in granulocyte progenitors, indicative of a global increase in productive transcription. These results suggest that ASXL1 inhibits productive transcription in granulocyte progenitors, identifying a new role for this epigenetic regulator in myeloid development.

PubMed Disclaimer

Conflict of interest statement

Competing Interests

B.J.D. potential competing interests-- SAB: Aileron Therapeutics, Therapy Architects (ALLCRON), Cepheid, Vivid Biosciences, Celgene, RUNX1 Research Program, Novartis, Gilead Sciences (inactive), Monojul (inactive); SAB & Stock: Aptose Biosciences, Blueprint Medicines, EnLiven Therapeutics, Iterion Therapeutics, Third Coast Therapeutics, GRAIL (SAB inactive); Scientific Founder: MolecularMD (inactive, acquired by ICON); Board of Directors & Stock: Amgen; Board of Directors: Burroughs Wellcome Fund, CureOne; Joint Steering Committee: Beat AML LLS; Founder: VB Therapeutics; Research Funding: EnLiven Therapeutics; Clinical Trial Funding: Novartis, Bristol-Myers Squibb, Pfizer; Royalties from Patent 6958335 (Novartis exclusive license) and OHSU and Dana-Farber Cancer Institute (one Merck exclusive license and one CytoImage, Inc. exclusive license). The remaining authors have no conflicts to report.

Figures

Figure 1.
Figure 1.. Single Cell RNA Reveals a Granulocyte Maturation Defect in Asxl1Δ/Δ mice at the point of cell cycle exit.
A. Bone marrow was isolated from Asxl1WT and Asxl1Δ/Δ mice 4 weeks and 6 months after induction of recombination with Poly I:C (n=3–4/group). Lineage positive cells were depleted using immunomagnetic purification and labeled with the indicated CITE-seq antibodies. Each individual mouse was labeled with a unique anti CD45 HTO antibody allowing for mouse-level bioinformatic deconvolution. Single cell transcriptional profiling was then performed using the Chromium platform (10X Genomics). UMAP projection demonstrating transcriptionally defined clusters identified using published datasets and data integration. Marker genes defining transcriptional cell clusters. B. UMAP projection demonstrating clusters defined by CITE-Seq. C. UMAP projections split by genotype (Asxl1WT and Asxl1Δ/Δ) and timepoint (4 weeks and 6 months) post induction of recombination. Circle surrounding terminal neutrophil populations D. Cell trajectories for all lineages and expanded view of granulocytic lineage. E. Linearized granulocyte trajectory showing transcriptional and CITE-seq clusters along with expression of key marker genes, cell cycle phase (phase), and CytoTRACE score. Arrows indicate point of divergence between Asxl1WT and Asxl1Δ/Δ.
Figure 2.
Figure 2.. Asxl1 Deletion Leads to Hyperactivation of a Myc Transcriptional Signature in Granulocyte Progenitors.
A. Schematic of CausalPath analysis which utilizes literature derived gene regulatory networks and gene correlations from the query dataset to predict causal relationships. B. Number of network edges as a measure transcriptional network complexity between Asxl1WT and Asxl1Δ/Δ mice. C. Differential MYC network activity in Asxl1Δ/Δ mice relative to wild type controls along the granulocytic lineage 6 months post induction of recombination. Network with a reduced FDR threshold (<0.025) shown to reduce complexity for the purposes of visualization. D. Differential network activation in granulocyte progenitor population 6 months post induction of recombination. E. Feature plots of Myc expression in Asxl1WT and Asxl1Δ/Δ mice. Note the increased density and intensity of blue MYC expressing cells in Asxl1Δ/Δ mice. F. Myc expression along granulocyte trajectory. G. Myc expression in terminal granulocyte progenitors (Pseudotime 15–20).
Figure 3.
Figure 3.. ASXL1 Deletion Does Not Substantially Impact the Landscape of Covalent Histone Modifications in Developing Myeloid Cells.
A. Bone marrow from Asxl1WT and Asxl1Δ/Δ mice was harvested 6 months after induction of recombination via poly I:C administration, maturing granulocyte lineage cells isolated by FACS, and subjected to CUT&Tag for H3K27me3. Spearman Correlation of Genome-wide H3K27me3 signal in indicated bone marrow sub-populations. B. Representative tracks of H3K27me3 signal in indicated bone marrow sub-populations. C. Mean normalized read density at H3K27me3 peaks in indicated bone marrow sub populations. D. RPKM values for reads in peaks for indicated histone marks in CD133 purified granulocytic progenitors. E. Mean normalized read density for indicated histone marks at Myc target genes as measured by CUT&Tag in CD133-granulocytic progenitors from CausalPath analysis in Figure 2.
Figure 4.
Figure 4.. ASXL1 Deletion Leads to an Increase in RNAPII Pause-Release.
A. Spearman correlation of histone mark or RNAPII CUT&Tag in CD133 positive granulocyte progenitors from Asxl1WT mice (n=2–4/group) and published ASXL1 ChIP-seq. B. Schematic depicting the calculation of RNAPII pause-index. C. Cumulative distribution of RNAPII pause-indices at genes bound by Myc and RNAPII in Asxl1WT and Asxl1Δ/Δ mice (n=4/group). D. Cumulative distribution of RNAPII pause-indices at genes bound by RNAPII and lacking a Myc peak in Asxl1WT and Asxl1Δ/Δ mice (n=4/group). Median pause index difference between Asxl1WT and Asxl1Δ/Δ conditions. Statistical significance between RNAPII pause-index distributions in Asxl1WT and Asxl1Δ/Δ conditions evaluated using a KS-test. E. Mean signal at all genes bound by RNAPII. Representative RNAPII tracks from genes with differential RNAPII pausing in from Asxl1WT and Asxl1Δ/Δ mice.

References

    1. Gelsi-Boyer V, Brecqueville M, Devillier R, Murati A, Mozziconacci M-J, Birnbaum D. Mutations in ASXL1 are associated with poor prognosis across the spectrum of malignant myeloid diseases. J Hematol Oncol 2012; 5: 12. - PMC - PubMed
    1. Kim T, Tyndel MS, Zhang Z, Ahn J, Choi S, Szardenings M et al. Exome sequencing reveals DNMT3A and ASXL1 variants associate with progression of chronic myeloid leukemia after tyrosine kinase inhibitor therapy. Leukemia Research 2017; 59: 142–148. - PubMed
    1. Pratcorona M, Abbas S, Sanders MA, Koenders JE, Kavelaars FG, Erpelinck-Verschueren CAJ et al. Acquired mutations in ASXL1 in acute myeloid leukemia: prevalence and prognostic value. 1 2012; 97: 388–392. - PMC - PubMed
    1. Tefferi A, Guglielmelli P, Lasho TL, Rotunno G, Finke C, Mannarelli C et al. CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients. Leukemia 2014; 28: 1494–1500. - PubMed
    1. Abelson S, Collord G, Ng SWK, Weissbrod O, Mendelson Cohen N, Niemeyer E et al. Prediction of acute myeloid leukaemia risk in healthy individuals. Nature 2018; 559: 400–404. - PMC - PubMed

Publication types